Partnership drives commercial excellence through precision
engagement to benefit patients in need of options
BAUDETTE, Minn. and PLEASANTON, Calif., June 21,
2022 /PRNewswire/ -- ANI Pharmaceuticals, Inc.
(Nasdaq: ANIP) and Veeva Systems (NYSE: VEEV) today announced a
collaboration to define and operationalize data-driven commercial
strategies for ANI's new Rare Disease Business Unit. ANI is using
software, data, and services from Veeva to establish the digital
foundation for the launch of the business unit's first commercially
available product in the U.S.
"To serve rare disease patients with high unmet medical needs,
we need to be agile, data-driven, and efficient," said Christopher Mutz, head of rare disease at ANI.
"With Veeva as our trusted partner, we accelerated launch readiness
and equipped new sales, medical, and marketing teams with the
digital tools they need — all with the speed and precision
warranted by such an important milestone."
ANI recently announced the U.S. commercial availability of
Purified Cortrophin® Gel (Repository Corticotropin Injection USP)
80 U/mL. To prepare for this launch, ANI adopted the complete suite
of Veeva Commercial Cloud solutions across its business,
including software for multichannel engagement and content
management, along with longitudinal patient data for customer
segmentation.
"ANI now has a digital foundation that supports its
patient-centric approach to commercialization," said Paul Shawah, executive vice president of
commercial strategy at Veeva. "The company is advancing its mission
by leveraging data to uncover key patient groups as well as the
providers who care for them and empowering its field teams to
create meaningful connections."
Veeva Business Consulting also helps the company use
advanced analytics to continuously optimize for the most precise
and impactful sales and medical interactions. This allows ANI's
field force to identify new healthcare professionals, while
delivering actionable insights so they can best engage with them.
Learn more about how ANI launched at speed and scale in an upcoming
fireside chat webinar on July 19.
Additional Information
For more on Veeva Commercial Cloud, visit:
veeva.com/commercial-cloud/
Connect with Veeva on LinkedIn:
linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
About Veeva Systems
Veeva is the global leader in cloud software for the life
sciences industry. Committed to innovation, product excellence, and
customer success, Veeva serves more than 1,000 customers, ranging
from the world's largest pharmaceutical companies to emerging
biotechs. As a Public Benefit Corporation, Veeva is committed to
balancing the interests of all stakeholders, including customers,
employees, shareholders, and the industries it serves. For more
information, visit veeva.com.
About ANI Pharmaceuticals,
Inc.
ANI Pharmaceuticals is a diversified biopharmaceutical company
serving patients in need by developing, manufacturing, and
marketing high quality branded and generic prescription
pharmaceutical products, including for diseases with high unmet
medical need. Our team is focused on delivering sustainable growth
by building a successful Purified Cortrophin® Gel franchise,
strengthening our generics business with enhanced development
capability, innovation in established brands and leveraging our
North American manufacturing capabilities. For more information,
please visit www.anipharmaceuticals.com.
ANI Forward-Looking
Statements
To the extent any statements made in this release relate to
information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements may be identified by words
such as "anticipates," "will," "expects," "plans," "potential,"
"future," "believes," "intends," "continue," other words of similar
meaning, derivations of such words, and the use of future dates.
These forward-looking statements include, but are not limited to,
statements related to the commercial launch of Cortrophin Gel.
Risks and uncertainties that may cause ANI's actual results to be
materially different than those expressed in or implied by such
forward-looking statements include, but are not limited
to, the costs involved in commercializing Cortrophin Gel,
general business and economic conditions, increased
competition and strategies employed by competitors, uncertainties
regarding the COVID-19 pandemic, market trends for our products,
regulatory environment and changes, and other risks and
uncertainties that are described in ANI's Annual Report on Form
10-K, quarterly reports on Form 10-Q, and other periodic reports
filed with the U.S. Securities and Exchanges Commission.
Any forward-looking statements in this news release speak only
as of the date of this news release and are based on ANI's current
beliefs, assumptions, and expectations. Except as required by law,
ANI undertakes no obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Veeva Forward-Looking
Statements
This release contains forward-looking statements regarding
Veeva's products and services and the
expected results or benefits from use of
our products and services. These statements are based on
our current expectations. Actual results could differ
materially from those provided in this release and we have no
obligation to update such statements. There are numerous risks that
have the potential to negatively impact our results, including
the risks and uncertainties disclosed in our filing on Form 10-Q
for the period ended April 30, 2022,
which you can find here (a summary of risks which may
impact our business can be found on pages 37 and 38), and in our
subsequent SEC filings, which you can access at sec.gov.
Veeva Systems Media Contact
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
ANI Pharmaceuticals Media Contact
Angela Salerno-Robin
dna Communications
212-445-8219
ASalerno-Robin@dna-comms.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ani-pharmaceuticals-adopts-veeva-commercial-cloud-to-better-support-rare-disease-patients-301571798.html
SOURCE Veeva Systems